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Abstract
Background: Alpha-tocopherol ether-linked acetic acid (a-TEA), an analog of vitamin E (RRR-alpha-tocopherol), is a
potent and selective apoptosis-inducing agent for human cancer cells in vivo and in vitro. a-TEA induces apoptosis
via activation of extrinsic death receptors Fas (CD95) and DR5, JNK/p73/Noxa pathways, and suppression of anti-
apoptotic mediators Akt, ERK, c-FLIP and survivin in breast, ovarian and prostate cancer cells.
Results: In this study, we demonstrate that a-TEA induces the accumulation of cell surface membrane ceramide,
leading to co-localization with Fas, DR5, and FADD, followed by activation of caspases-8 and -9 and apoptosis in
human MDA-MB-231 breast cancer cells. a-TEA treatment leads to increased acid sphingomyelinase (ASMase)
activity by 30 min, peaking at 4 hrs, which is correlated with ASMase translocation from cytosol to the cell surface
membrane. Functional knockdown of ASMase with either the chemical inhibitor, desipramine, or siRNA markedly
reduces a-TEA-induced cell surface membrane accumulation of ceramide and its co-localization with Fas, DR5, and
FADD, cleavage of caspases-8 and -9 and apoptosis, suggesting an early and critical role for ASMase in a-TEA-
induced apoptosis. Consistent with cell culture data, immunohistochemical analyses of tumor tissues taken from a-
TEA treated nude mice bearing MDA-MB-231 xenografts show increased levels of cell surface membrane ceramide
in comparison to tumor tissues from control animals.
Conclusion: Taken together, these studies demonstrate that ASMase activation and membrane ceramide
accumulation are early events contributing to a-TEA-induced apoptosis in vitro and perhaps in vivo.
Background
Specialized domains of cell surface membranes termed
lipid rafts/platforms or lipid microdomains play a key
role in the spatial organization of receptors and signal-
ing molecules [1-3]. Ceramide-enriched lipid microdo-
mains can be formed by increased amounts of ceramide
in cell surface membranes which is regulated by sphin-
gomyelinase (SMase) hydrolysis of raft-associated sphin-
gomyelin to ceramide [2,3]. Once ceramide-enriched
microdomains are formed, Fas/FasL and DR5/TRAIL as
well as other signaling mediators become clustered and
can be activated in either a ligand-dependent or -inde-
pendent manner [4-6]. Clustering of Fas or DR5 can
result in rapid association of these receptors with adap-
ter protein FADD [7], which recruits the initiation cas-
pase-8 to its death effector domain, initiating apoptosis
via death inducing signaling complex (DISC) [8]. Pre-
vention of raft reorganization into larger platforms by
inactivation of acid sphingomyelinase (ASMase), renders
cells resistant to Fas clustering and apoptosis [9], indi-
cating that ASMase/ceramide plays an important role in
death receptor-mediated apoptosis.
a-TEA (RRR-alpha-tocopherol ether-linked acetic acid
analog), a derivative of vitamin E (RRR-alpha-toco-
pherol), is a potent pro-apoptotic agent for a variety of
human cancer cells, including breast cancer cells in vivo
and in vitro [10-24]. a-TEA does not induce apoptosis
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immortalized, nontumorigenic breast cells (MCF-10A
cells) [17] and produces no signs of toxicity when given
to mice [10,11,19,24,25]. Previous studies utilizing var-
ious functional knockdown strategies (siRNA, neutraliz-
ing antibodies, transfection of dominant negative
proteins and small chemical inhibitors) show that a-
TEA-induced apoptosis in human breast, ovarian and
prostate cancer cells is mediated by Fas and DR5 death
receptor signal transduction via FADD or Daxx and
involves both caspase-8 and mitochondrial-dependent
signal transduction events [15,16,18,20,21]. However,
mechanisms involved in a-TEA induced Fas- and DR5-
dependent apoptotic signaling are not fully understood.
Here we report that a-TEA initiates activation of
ASMase via translocation from the cytosol to the cell
surface membrane, leading to accumulation and aggre-
gation of membrane ceramide domains enriched with
death signaling mediators; Fas, DR5 and their adaptor
FADD, as an essential early event in a-TEA induced Fas
and DR5 dependent apoptosis.
Materials and methods
Chemicals
a-TEA (F.W. = 488.8; 40 μM) was dissolved in ethanol
as stock solution as described previously [10]. Desipra-
mine, an ASMase inhibitor, GW4869, a neutral SMase
(NSMase) inhibitor, and fumonisin B1, a ceramide
synthase inhibitor, were obtained from Sigma-Aldrich
(St. Louis, MO). Myriocin, a serine palmitoyltransferase
inhibitor of the de novo ceramide synthesis pathway,
was obtained from BioMol (Plymouth Meeting, PA).
Cell Culture
Triple-negative (ER
-,P R
-,H e r - 2
-) MDA-MB-231 human
invasive ductal carcinoma, basal-like breast cancer cells
(American Type Culture Collection, Manassas, VA)
were cultured in MEM media with 10% FBS. For experi-
ments, FBS was reduced to 2%. All cells were plated at
1.5 × 10
5 cells/well in 12 well plates for apoptosis ana-
lyses, 3 × 10
5 cells/well in 6 well plates for immuno-
fluorescence staining andF A C Sa n a l y s e s ,a n d2×1 0
6
cells/100 mm
2 or 6 × 10
6 cells/150 mm
2 dishes for wes-
tern blot analyses. Cells were allowed to attach over-
night before treatment initiation. The cells were treated
with a-TEA at 40 μM with equivalent level of solvent
(0.1% ethanol) serving as vehicle control (VEH).
Quantification of apoptosis
Apoptosis was quantified by Annexin V-FITC/PI assay
(Invitrogen, Carlsbad, CA) following manufacturer’s
instructions. The Annexin V-FITC/PI assay measures
amount of phosphatidylserine on the outer surface of
the plasma membrane (a biochemical alteration unique
to membranes of apoptotic cells) and amount of propi-
dium iodide (PI), a DNA binding dye that does not
cross the plasma membrane of viable cells but readily
enters dead cells or cells in the late stages of apoptosis.
Fluorescence was measured using Fluorescence Acti-
vated Cell Sorter (FACS) analyses with a FACSCalibur
flow cytometer. Data were analyzed using CellQuest
software (BD Biosciences, San Jose, CA). Cells displaying
phosphatidylserine on their surface (positive for
Annexin-V fluorescence) were considered to be
apoptotic.
Small interfering RNA (siRNA) transfection
A scrambled RNA duplex that does not target any
known genes was used as the non-specific negative con-
trol for RNAi (referred to as control siRNA). Transfec-
tion of MDA-MB-231 cells with siRNAs to ASMase or
control (Ambion, Austin, TX) was performed in 100
mm
2 cell culture dishes at a density of 2 × 10
6 cells/dish
using Lipofectamine-2000 (Invitrogen) and siRNA
duplex, resulting in a final siRNA concentration of 30
nM following the company’s instructions. One day after
transfection initiation, the cells were re-cultured in 100
mm
2 dishes at 2 × 10
6 cells/dish and incubated for 1
day followed by treatments.
Western Blot analyses
Whole cell protein extracts were prepared and examined
by western blotting as described previously [26]. Pro-
teins at 30-50 μg/lane were separated by SDS-PAGE
and transferred to nitrocellulose (Optitran BA-S sup-
ported nitrocellulose, Schleicher and Schuell, Keene,
NH). Antibodies (1 μg/ml) to the following proteins
were used: poly (ADP-ribose) polymerase (PARP) (Santa
Cruz Biotechnology, Santa Cruz, CA), caspase-8 and
caspase-9 (Cell Signaling Technology, Beverly, MA), and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH;
made in house). Horseradish peroxidase conjugated
goat-anti-rabbbit or goat-anti-rabbbit secondary antibo-
dies (1:2000 dilution) (Jackson ImmunoResearch Labora-
tories, Rockford, IL) was used.
Immunofluorescent staining detection of ASMase,
ceramide, DR5, Fas and FADD
Cellular location of ASMase, ceramide, DR5, Fas and
FADD was determined using immunofluorescent stain-
ing. Treated and control cells were washed two times
with PBS and fixed with fresh 4% paraformaldehyde in
PBS for 15 min at room temperature. After 3 washes
with PBS, cells were permeated with 0.1% Triton X-100
for 15 min at room temperature followed by incubating
the cells with blocking buffer (2% FBS in PBS) for 1 hr,
and then incubating the cells with reaction buffer (1%
FBS in PBS) overnight at 4°C with antibodies (20 μg/ml)
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ciences, San Jose, CA), ASMase and Fas (Santa Cruz
Biotechnology), and antibody (4 μg/ml) to ceramide
(Sigma-Aldrich). Samples were washed three times with
PBS and stained for 1 hr with Texas Red donkey anti-
rabbit IgG (Santa Cruz Biotechnology) for DR5, Alexa
Fluor 594 goat anti-mouse IgG (Invitrogen) for Fas and
FADD, Alexa Fluor 488 goat anti-mouse IgM and FITC-
conjugated rabbit anti-goat IgG (Jackson ImmunoRe-
search Laboratories) for ceramide and ASMase at 10 μg/
ml, respectively, in reaction buffer. Cells were washed
three times with PBS. Images were acquired using fluor-
escent microscopy or laser-scanning confocal
microscope.
Detection of ceramide expression in cell surface
membranes of living cells
The expression of cell surface membrane ceramide was
determined by immunostaining analyses using FACS or
fluorescent microscopy. 2 × 10
6 cells were collected,
washed in ice-cold PBS, and blocked with blocking buf-
fer (2% FBS in PBS) for 20 min on ice. Cells were re-
washed and incubated for 1 hr with 4 μg/ml monoclonal
ceramide antibody (15B4, Sigma) on ice, followed by ice-
cold PBS washing and incubation with Alexa fluor 488
goat anti-mouse IgM at 10 μg/ml on ice for 30 min.
After two PBS washes, cells were analyzed immediately
using a FACScan flow cytometer or by immunofluores-
cence microscopy for cell surface membrane ceramide.
ASMase Activity Assay
ASMase activity was determined using an acid sphingo-
myelinase assay kit (Echelon Biosciences Inc. Salt Lake
City, UT) following company’si n s t r u c t i o n s .C e l l sw e r e
disrupted in ice-cold lysis buffer [150 mM NaCl, 50 mM
Tris pH 7.4, 0.6% Triton X-100, and protease inhibitor
cocktail (Sigma-Aldrich)] for 20 min. Cellular debris was
removed after centrifugation at 10,000 × g for 5 min,
and 20 μg protein was used to determine ASMase activ-
ity. Reaction was stopped after incubation at 37°C for 2
hrs and analyzed using a fluorescence plate reader at
260 nm excitation and 460 nm emission.
Immunohistochemical detection of membrane ceramide
Archived formalin fixed tumor tissue from a MDA-MB-
231 xenograft study [27] was used to determine if
a-TEA induces elevated membrane ceramide in vivo.
Mice were euthanized after 24 days of a-TEA dietary
treatment (378 mg a-TEA/kg diet). Immediately upon
collection, tumors were fixed in formalin and archived
for immunohistochemical analyses [27]. Deparaffinized
5 micron sections were examined by IHC employing a
monoclonal antibody against ceramide (MID 15B4;
Sigma-Aldrich). Three tumors from control and a-TEA
treatment groups were analyzed. Deparaffinized sections
were placed in 10 mM sodium citrate buffer (pH 6.0)
and boiled 10 min for antigen unmasking. After rinsing,
sections were placed in PBS followed by incubating with
blocking buffer (2% FBS, 0.3% Triton X-100 in PBS) for
1 hr. After removal of blocking buffer, cells were incu-
bated with primary mouse anti-ceramide antibody
(4 μg/ml in 1% FBS/PBS) or mouse IgM (10 μg/ml for
negative control) overnight at 4°C. After 3 washes with
PBS for 10 min each, the sections were stained with
DakoCytomation LSAB + System-AP following the com-
pany’s instruction (Dako Carpinteria, CA) and DAPI.
Statistical Analysis
The student’s t-test was used to determine statistical dif-
ferences between treatment and control values. Differ-
ences were considered statistically significant at p < 0.05.
Results
a-TEA induces apoptosis in MDA-MB-231 human breast
cancer cells
a-TEA induces MDA-MB-231 cells to undergo apopto-
sis in a time dependent manner as measured by FACS/
Annexin V/PI analyses. Apoptosis was detected at
15 hrs after treatment with 40 μM a-TEA (Figure 1A
&1B). a-TEA treatment for 9 hrs did not show a signifi-
cant increase in percentage of apoptotic cells in compar-
ison with VEH control, whereas a-TEA treatments for
15 and 24 hrs produced a high percentage of apoptotic
cells, approximately, 33% and 57%, respectively, suggest-
ing that apoptosis occurred between 9-15 hrs. Data
from western immunoblotting analyses show cleavage of
caspases-8 and -9 in lower levels at 9 hrs, and higher
levels at 15 and 24 hrs after treatment (Figure 1C). Clea-
vage of PARP, an apoptotic marker, was detected at 15
and 24 hrs after treatment (Figure 1C).
a-TEA induces increased level of ceramide in cell surface
membrane
To see if a-TEA induces an increased level of ceramide
in the cell surface membrane, membrane ceramide
expression in a-TEA treated MDA-MB-231 cells was
determined by fluorescent microscopy or FACS analyses
of cells stained for ceramide (Figure 2). Microscopic
analyses showed that ceramide was aggregated in cell
surface membranes starting as early as 4 hrs and contin-
u e dt ob ee l e v a t e da t1 5h r sa f t e ra-TEA treatment in
comparison with VEH control (Figure 2A). In agreement
with the microscopic morphological data, FACS analyses
showed that cell surface membrane level of ceramide in
a-TEA treated cells were increased at 4 and 15 hrs (Fig-
ure 2B). These data show that a-TEA induces increased
and prolonged levels of ceramide, which is aggregated in
the cell surface membrane as early as 4 hrs.
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elevated ceramide-enriched membrane
The effects of a-TEA on the expression of cell mem-
brane death receptors Fas, DR5 and death adaptor pro-
tein FADD as well as membrane ceramide were
examined using immunofluorescent staining procedures
(Figure 3A, B, &3C). a-TEA induced increased levels of
ceramide in cell surface membrane in comparison to
VEH control and overlay (merge) of ceramide and
DAPI-stained nuclei with DR5, Fas, or FADD showed
the death mediators to be co-localized with ceramide
(Figure 3A, B, &3C). These data demonstrate that a-
TEA induced accumulation of DR5, Fas and FADD in
ceramide enriched cell surface membrane, suggesting
ceramide may be playing an important role in a-TEA-
induced apoptosis.
a-TEA activation of ASMase is an early event
To determine if ASMase is activated by a-TEA, ASMase
activity was measured using a colorimetric sphingomye-
linase assay kit. ASMase activity was increased from
105% at 30 min to a peak of 143% at 4 hrs and contin-
ued to be elevated at 9 hrs after a-TEA treatment in
comparison to VEH control (control = 100%) (Figure
4A). It is well established that activation of ASMase is
coupled with its translocation from intracellular com-
partments to the cell surface membrane [2]; therefore,
we determined whether activity of ASMase was asso-
ciated with relocalization of ASMase from the cytosol to
the membrane. Confocal microscopic imaging revealed
that a-TEA induces ASMase relocation from punctuate
cytosol location (see in VEH treated cells) to a diffuse
cell surface membrane location (arrows) by 4 hrs with
Figure 1 a-TEA induces apoptosis in human breast cancer cells. A & B, MDA-MB-231 cells were treated with 40 μM a-TEA for 9, 15, and 24
hrs. Apoptosis was determined by FACS/Annexin V assay (A) and depicted in graphic form (B). C, Western blot analyses were used to detect
cleavage of caspases-8, -9 and PARP. Data in A & C are representative of three experiments. Data in B is presented as means ± S.D. of three
independent experiments.
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treatment (Figure 4B). These data demonstrate that a-
TEA activation of ASMase via translocation of it from
cytosol to membrane is an early event.
ASMase inhibitor desipramine blocks a-TEA-induced
apoptosis
To investigate whether ASMase is involved in a-TEA-
induced apoptosis and if it produces increased levels of
ceramide at the cell surface, the sphingomyelin hydroly-
sis pathway was blocked by ASMase inhibitor desipra-
mine. Inhibition of ASMase blocked a-TEA-induced
apoptosis as documented by reduced ability of a-TEA
to induce cleavage of caspases 8 & 9 and PARP (Figure
5A). In contrast GW4869, an inhibitor of sphingomyelin
hydrolysis, myriocin, an inhibitor of de novo ceramide
synthesis and fumonisin B1, an inhibitor of the ceramide
salvage pathway had no effect on a-TEA-induced
apoptosis (data not shown). Assessment of ASMase
activity shows that desipramine blocks a-TEA-induced
increases in ASMase activityb y7 7 %( F i g u r e5 B ) ,c o n -
firming that desipramine is an effective ASMase inhibi-
tor. FACS analyses of ceramide stained cells show that
desipramine blocks the increase of ceramide at the cell
surface membrane in comparison with a-TEA treated
cells in the absence of ASMase inhibitor (Figure 5C),
indicating that anti-ceramide antibody (15B4) is specific
for recognizing membrane ceramide. Taken together,
these data suggest that ASMase is involved in a-TEA-
induced apoptosis and is involved in a-TEA-mediated
increases of ceramide at the cell surface.
siRNA to ASMase blocked a-TEA-induced apoptosis
To further confirm the role of ASMase in a-TEA-
induced apoptosis, siRNA to ASMase was used as an
alternative method to knock down ASMase and to
Figure 2 a-TEA induced increased levels and aggregation of ceramide in cell surface membranes. A, MDA-MB-231 cells were treated with
40 μM a-TEA for 4, 9 and 15 hrs (15 hrs for vehicle control). The living cells were collected and immunostained with antibody to ceramide.
Cellular membrane ceramide was assessed by fluorescence microscope. B, Samples from Figure 2a at 4 and 15 hrs time points were also
assessed by FACS for membrane expression of ceramide. All images are representative of three independent experiments.
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cell surface ceramide and induction of apoptosis. siRNA
to ASMase blocks a-TEA-induced increase in cell sur-
face membrane ceramide detected by anti-ceramide
antibody (15B4), further indicating that this antibody is
specific for recognizing membrane ceramide (Figure
6A). In addition, siRNA to ASMase significantly reduced
the ability of a-TEA to induce the cells to undergo
apoptosis (Figure 6B). Western blot analyses show that
the siRNA to ASMase reduced ASMase protein expres-
sion (Figure 6C), verifying silencing efficacy of siRNA to
ASMase. These data further demonstrate that ASMase
is involved in a-TEA-induced apoptosis and a-TEA-
mediated increase in ceramide at the cell surface.
ASMase is involved in a-TEA-induced accumulation of
DR5, Fas and FADD in elevated ceramide-enriched
membrane
To see whether ASMase-mediated increase of cell sur-
face ceramide is a contributor to a-TEA-induced
accumulation of DR5, Fas and FADD in elevated cera-
mide-enriched membrane, the effects of ASMase inhibi-
tor desipramine on a-TEA-induced co-localization of
cell membrane death receptors Fas and DR5, as well as
death adaptor protein FADD with ceramide were exam-
ined using immunofluorescent staining procedures (Fig-
ure 7A, B, &7C). As previously shown in Figure 3,
Figure (7A, B and 7C) shows that a-TEA induces accu-
mulation of DR5, Fas, and FADD in elevated ceramide-
enriched membrane in comparison to VEH control (Fig-
ure 7A, B, &7C) and desipramine (ASMase inhibitor)
reduces the ability of a-TEA-mediated events (Figure
7A, B, &7C). These data demonstrated that ASMase-
mediated increase of ceramide in cell surface membrane
is a contributor to a-TEA-induced accumulation of
DR5, Fas and FADD in elevated ceramide-enriched
membranes.
Diet supplemented with a-TEA induced membrane
ceramide accumulation in xenografted MDA-MB-231 cells
To determine if a-TEA induces increased levels of
membrane ceramide in vivo,w ee x a m i n e dm e m b r a n e
ceramide expression in 5 micron sections of tumor tis-
sue taken from a-TEA or control treated immune com-
promised Nu/Nu mice bearing MDA-MB-231
xenografts. The tumor volume and tumor weight for a-
TEA treatment group were significantly reduced in
comparison to the control group after 24 days of treat-
ment (p < 0.01) (Tumor volume data was published [27]
and tumor weight data is shown in Figure 8A). It is
important to note that no significant differences were
observed in body weights between control and a-TEA
treated groups. Previously published immunohistochem-
ical analyses showed that TUNEL positive cells in the a-
TEA treated group were significantly increased by 2.1
fold in comparison to control group [27]. Archived
tumor samples were analyzed for ceramide expression
by immunohistochemical analyses. Tumor tissue from
a-TEA dietary supplemented animals exhibited
increased levels of membrane ceramide (detected as
brown stained circles around clear; i.e., white color of
nuclei following merge) in comparison with absence of
membrane-localized ceramide in control tumor tissue
(Figure 8B). These data show that a-TEA increases
membrane ceramide in vivo, suggesting that increased
membrane ceramide plays a role in a-TEA antitumor
actions in vivo.
Discussion
a-TEA exhibits selective anticancer properties both in
vitro and in vivo [10-24]. Mechanisms whereby a-TEA
induces tumor cells to undergo apoptosis include activa-
tion of both death receptors (Fas and DR5) and JNK/
p73/Noxa pro-apoptotic pathways; as well as
Figure 3 a-TEA induces accumulation of DR5, Fas, FADD and
ceramide in cell surface membranes. A, B & C, Cells were treated
with 40 μM a-TEA or vehicle (VEH) for 15 hrs and cellular
localization of DR5, Fas, FADD (red channel) and ceramide (green
channel) were detected by immunostaining in paraformaldehyde
fixed cells. Merge = overlay of ceramide (green channel) + DAPI
(blue channel) + DR5 or Fas, or FADD (red channel). All data are
representative images of three separate experiments.
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FLIP and survivin [15,16,18,20,21,28,29]. However, less
is known about initiating events that lead to these desir-
able dual activities. New findings reported here include:
1) a-TEA triggers ASMase activation which involves
translocation from cytosol to the cell surface membrane;
2) ASMase activation proceeds a-TEA-induced increase
levels and aggregation of ceramide in the cell surface
membrane; 3) a-TEA induces accumulation of DR5, Fas
and FADD in elevated ceramide-enriched membrane;
and 4) ASMase inhibitors (desipramine and siRNA to
ASMase) decrease a-TEA-mediated membrane changes
and apoptosis.
Based on these data we propose the following
sequence of events whereby a-TEA induces apoptosis in
human MDA-MB-231 breast cancer cells (summarized
in Figure 9). Within 30 min of a-TEA treatment
ASMase activity starts to increase, and by 4 hrs there is
evidence of ASMase translocation from the cytosol
(intracellular compartments such as lysosomes) to the
cell surface membrane. ASMase translocation is
associated with increased levels of cell surface mem-
brane ceramide. Co-localization of ceramide with Fas,
DR5, and FADD and evidence of cleaved caspases 8 and
9 are observed by 9 and 15 hrs, while evidence of apop-
tosis (Annexin V expression and PARP cleavage) is
observed at 15 and 24 hrs. Inhibition of ASMase activity
using desipramine or ASMase expression using siRNA
reduces the ability of a-TEA to increase cell surface
membrane levels of ceramide, DR5, Fas and FADD and
reduces a-TEA-induced apoptosis. In summary, a-TEA-
induced apoptosis triggers an early ASMase-dependent
generation of ceramide in the cell surface membrane of
human MDA-MB-231 breast cancer cells, which is
required for Fas and FADD relocation to the cell surface
membrane and DR5, Fas and FADD co-localization in
ceramide-enriched membrane domains.
The concept that vitamin E analogs can increase
sphingomyelinase activity and ceramide in conjunction
with apoptosis induction has been reported previously
in other cancer cell types [30,31]. Weber et al.[ 3 0 ]
showed that Jurkat human T lymphoma cells treated
Figure 4 a-TEA induces ASMase activation. A, ASMase activity was detected using the Acid Sphingomyelinase Assay kit (Echelon) at different
time points following treatment with 40 μM a-TEA. B, Cellular localization of ASMase following treatment with 40 μM a-TEA for 4 and 9 hrs (9
hrs vehicle treatment) was detected (green channel) using immunofluorescent staining of paraformaldehyde fixed cells. Arrows in a-TEA treated
cells point to membrane ASMase versus arrows in vehicle control point to cellular dispersion of ASMase.
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nate (called vitamin E succinate), exhibited altered mito-
chondrial structure, generation of free radicals, and
activation of the sphingomyelin cycle as early events in
vitamin E succinate-initiated pro-apoptotic signaling.
Based on a partial suppression of vitamin E succinate-
induced apoptosis by the ASMase inhibitor desipramine,
they demonstrated that activation of ASMase played a
role in vitamin E succinate-induced apoptosis [30]. Our
data are in agreement showing that ASMase activation
is involved in apoptosis induced by another vitamin E
derivative, a-TEA. Thus, activation of ASMase may be a
common event in vitamin E analog-induced apoptosis
that is not cell type specific. Likewise, our data are in
agreement with the studies of Gu et al. [31] who
showed that vitamin E succinate-induced apoptosis in
human head and neck squamous cell carcinomas
(HNSCC) was correlated with early increases in sphin-
gomyelinase activity and ceramide levels. Furthermore,
our data showing increased immunostaining of ceramide
within cell surface membranes of tumor tissue derived
from breast cancer bearing immune compromised mice
fed a-TEA are in agreement with Gu et al.’sd a t as h o w -
ing a significant degree of immune staining of ceramide
within the cellular membrane of HNSCC JHU-022
tumor tissue obtained from xenografted immune
Figure 5 ASMase inhibitor desipramine blocks a-TEA-induced apoptosis. MDA-MB-231 cells were pre-treated with 12.5 μM desipramine for
2 hrs followed by treating the cells with 40 μM a-TEA for different time periods. A, Western blot analyses of cellular lysates were performed to
detect cleavage of caspases-8 &-9 and PARP. B, ASMase activity was detected using the Acid Sphingomyelinase Assay kit (Echelon). C, Ceramide
levels in cell surface membranes were detected by FACS analyses after reaction of living cells with primary ceramide antibody and fluorescence
labeled secondary antibody after 4 hours of a-TEA treatment. Data are representative of three independent experiments. Data in B are presented
as means ± S.D. of three independent experiments. (* = Significantly different, P < 0.05).
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[31]. Thus, the ability of vitamin E analogs to induce
elevated cell surface membrane levels of ceramide in
cancer cells occurs both in cell culture and in vivo [31].
An important difference between the studies reported
here and the studies cited above, is that we report a
connection between early activation of ASMase and sub-
sequent elevated cell surface membrane ceramide with
co-localization with Fas, DR5 and FADD in membrane.
Previously, we showed that a-TEA treatments increased
Fas and Fas L mRNA and protein levels, as well as levels
of cell surface membrane-associated Fas in human
ovarian and prostate cancer cells and that functional
knockdown of Fas and Fas-L attenuated a-TEA-induced
apoptosis [20,21]. Recently, we showed that a-TEA
treatment increases the expression of TRAIL and DR5
and that functional knockdown of DR5 and TRAIL
blocked a-TEA’s ability to induce apoptosis [15,16].
Thus, data suggest that a-TEA induction of apoptosis
involves, at least in part, activation of extrinsic death
receptor signaling. Information reported here suggests
that a-TEA triggering of apoptosis via extrinsic death
receptors involves upregulation of ceramide-enriched
membrane domains via activation of ASMase.
Figure 6 siRNA to ASMase blocks a-TEA-induced apoptosis. MDA-MB-231 cells were transfected with siRNAs to ASMase or control for 24 hrs
followed by treating the cells with 40 μM a-TEA for 4 hrs. A, Ceramide levels in cellular membrane were detected by FACS analyses after
immunofluorescent staining of living cells with primary ceramide antibody and fluorescence labeled secondary antibody. B, Annexin V/FACS
analyses showed that siRNA to ASMase blocked a-TEA induced apoptosis. C, Western blot analyses was used to verified silencing efficiency of
siRNA to ASMase using GAPDH as loading control. Data in A & C are representative of two independent experiments. Data in B are presented as
means ± S.D. of three independent experiments. (* = significantly different, P < 0.05).
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occur via sphingomyelinase catalyzed hydrolysis of
sphingomyelin at the membrane. ASMase exists in two
forms, a lysosomal and a secretory form [32]. Secretory
ASMase translocates onto the outer leaflet of the plasma
membrane from an intracellular location, presumably
vesicular stores, to release ceramide within the raft-asso-
ciated sphingomyelin pool, generating the ceramide
required for raft clustering in response to various stress
stimuli, including irradiation, death receptors signaling,
and chemotherapeutic agents such as cisplatin and dox-
orubicin [32-38]. Therefore, ceramide in the cell surface
membrane can function as an upstream or downstream
mediator of extrinsic death receptor mediated apoptosis.
Fas ligand and TRAIL have been shown to trigger accu-
mulation of ceramide in membranes via recruitment of
DISC and activation of caspase 8 [33,34,38], while
another study showed that UV-induced accumulation of
ceramide is FADD/caspase-8 independent [32]. Further-
more, ceramide-mediated formation of Fas- or DR5-
clusters within the ceramide platform leads to triggering
of death receptor-mediated apoptosis [4,9,33-35] which
can be either ligand-depende n to r- i n d e p e n d e n t[ 3 2 ] .
Data presented here show that increased levels and
aggregation of membrane ceramide occur as early as 4
hrs after a-TEA treatment, while DR5/Fas/FADD mem-
brane accumulation was not observed until 9 hrs after
a-TEA treatment, suggesting that ceramide increase and
aggregation may be an upstream event in a-TEA-
induced Fas- and DR5-mediated apoptosis.
Several mechanisms have been proposed to be
involved in the activation of ASMase, including ROS
[33,39], lysosomal anionic lipids (bismonoacylglycero-
phosphate) and sphingolipid activator protein SAP-C
[ 4 0 ] .R e c e n td a t as h o wt h a tP K C δ contributes to the
translocation and activation of ASMase via
Figure 7 ASMase is involved in a-TEA-induced accumulation of DR5, Fas, FADD and ceramide in cell surface membranes. Cellular
localization of DR5, Fas and FADD, as well as ceramide were detected by immunofluorescent staining of paraformaldehyde fixed cells with
primary antibodies to DR5, Fas, FADD, and ceramide followed by fluorescent labeled secondary antibody. All data are representative of three
independent experiments.
Li et al. Cancer Cell International 2010, 10:40
http://www.cancerci.com/content/10/1/40
Page 10 of 14phosphorylation of ASMase at ser-508 by PMA [37].
How a-TEA regulates ASMase activation is not known.
Our preliminary data do not support the role of ROS in
a-TEA-induced ASMase activation since ROS was not
induced by a-TEA and the antioxidant NAC did not
block a-TEA-induced increases in the levels of mem-
brane ceramide (data not shown). Since a-TEA is a
detergent-like lipid it is possible that a-TEA targets
lysosomes initiating activation of ASMase. This remains
to be determined.
Ceramide action is determined within the context of
other stimuli and by the subcellular location of its pro-
duction. Beside ASMase hydrolysis of sphingomyelin to
mediate ceramide levels at the cell surface, there are two
more pathways in which intracellular ceramide can be
generated, namely, the de novo synthesis pathway
(located in the endoplasmic reticulum) and the salvage
pathway (located in late endosomes/lysosomes) [41].
Both of these pathways generate ceramide and others
metabolites, which may contribute to apoptosis
Figure 8 a-TEA induced membrane ceramide accumulation in tumor tissue in vivo. A, Mean tumor weight ± S.D. for a-TEA treatment and
control groups at euthanasia (N = 10). B, Tumor tissue sections (5 microns) from a-TEA treated and control were stained for ceramide by
immunohistochemistry (brown) and with the DNA-fluorescent label DAPI (blue), and the two images were merged. Note: After merging the anti-
ceramide stained tissue obtained from regular light with the blue nuclear staining obtained from UV light, the nuclear color turns to white in
the merge image. Images are representative of three samples each of treatment and control group.
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role at the cell surface. For example; dihydroceramide,
an intermediate in the de novo synthesis pathway, has
been reported to trigger apoptosis and is upregulated by
g-tocopherol [42]. Glucosylceramide, an intermediate in
the salvage pathway, shows anti-apoptotic properties
and can be converted to ceramide by cerebrosidase (glu-
cohydrolases) [43]. Whether a-TEA regulates these
pathways is not known and beyond the scope of this
studies; however, we do know that de novo synthesis
pathway is not involved in a-TEA-induced apoptosis
based on the fact that the de novo ceramide synthesis
inhibitors myriocin and fumonisin B1 did not block a-
TEA-induced apoptosis (data not shown). These inhibi-
tor studies also suggest that ceramide synthase-mediated
ceramide may not be involved in a-TEA-induced apop-
tosis since fumonisin B1, an inhibitor of ceramide
synthase, did not block a-TEA- induced apoptosis.
To study how a-TEA regulates ceramide levels in cel-
lular membranes we used anti-ceramide antibody
(15B4), which provides special benefit to study ceramide
in its cellular context, such as subcellular localization of
ceramide. Although this antibody has been used in
many studies, the specificity of this antibody is still
questioned. For example, lipid overlay assays show that
the 15B4 anti-ceramide antibody recognizes not only
C16- and C24-ceramide, but also other lipids such as
dihydroceramide, sphingomyelin and phosphatidylcho-
line [44]. However, it is highly specific for ceramide and
does not cross-react with sphingomyelin, cholesterol or
other phospholipids under more physiologically relevant
in vitro and in vivo conditions [34,44]. In the studies
reported here, both ASMase inhibitor desipramine and
siRNA to ASMase blocked a-TEA-induced increases in
15B4 antibody-recognized phospholipids in membrane
clearly indicating that anti-ceramide (15B4) is specific
for recognizing membrane ceramide and confirming
that a-TEA effects are dependent on ASMase-mediated
ceramide increases in membrane.
Conclusion
In summary, our findings demonstrate that activation of
ASMase, leading to increases in cell surface membrane
ceramide, is a critical early event for extrinsic death
receptor signaling in a-TEA-induced apoptosis. This is
the first study that identifies possible initiation event in
a-TEA-induced apoptosis.
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